Pascal Touchon, Atara Biotherapeutics CEO
EC approves first allogeneic T cell therapy for rare post-transplant complication
The European Commission signed off on the continent’s first allogeneic T cell therapy Monday. And for its maker Atara Biotherapeutics, the approval marks the biotech’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.